DCAT Value Chain Insights’ Production to Prescription

Parenteral drugs have accounted for between 40% and 50% of new drug approvals over the past five years. CDMOs/CMOs continue to expand. For the text version of this article visit dcatvci.org. Key topics: (see Chapter Markers in drop down menu in audio player above) Active area of investment (1:13) Baxter BioPharma Solutions (1:25) PCI Pharma Services (2:07) Alcami (3:22) Catalent (4:31) Vetter (5:4...

Escalating energy prices are impacting global manufacturing and supply chains. In the EU, leaders are proposing measures to alleviate pricing pressures. What’s the plan? Key topics: (see Chapter Markers) Economic recovery brings pricing pressures Rising energy costs and the bio/pharma manufacturing value chain  Rising energy costs: call for action in the EU  Ripple effect throughout industrial sup...

Which modality, small molecules or biologics, leads among the top-selling products? A look at the top-selling products industry-wide and blockbusters from select leading bio/pharma companies provides the answer. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Modality of top-selling products New drug approvals: small molecules versus biologics Potential b...

Drug delivery is important not only for ensuring bioavailability for therapeutic benefit but also for product differentiation and market success. DCAT Value Chain Insights highlights technology advances in drug delivery for injectable and solid-dosage drugs and other products from recent start-ups, partnering deals, and mergers and acquisitions. For the text version of this article visit dcatvci.o...

What have been the key developments in 2021 thus far in the CDMO market? In this podcast we take a look at the increasing participation by CDMOs in COVID-19 vaccine manufacturing and robust mergers and acquisition activity that have marked the first half of 2021. What are the implications, and what can be expected going forward? For the text version of this article visit dcatvci.org . Key topics:...

FDA Addresses Supply Constraints Due to COVID-19; Plus, Packaging Suppliers Expand  In this podcast we take a look at the FDA’s new guidance to facilitate changes to container-closure-system components due to supply constraints, plus updates from suppliers of materials used to deliver COVID-19 vaccines, treatments and other parenteral drugs. For the text version of this article visit dcatvci.org ....

Although the COVID-19 pandemic dominated the headlines  in 2020, there were other key developments in 2020. In this year in review, we look at the other key developments in 2020, including new product approvals, noteworthy deals, and other developments making the news. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) 2020 in Review: The Top 10 Developments...

In this podcast we feature an article about what and who is behind Viatris, the new company formed from the combination of Upjohn, Pfizer’s off-patent branded and generic established medicines business, and Mylan. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Rationale for the new company Inside the new Viatris: products Inside the new Viatris: manufact...

In this podcast we feature an article that looks at solid dosage manufacturing in terms of CDMO growth rates and recent product trends. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) New drug approvals and solid-dosage products CDMOs/CMOs: inside the numbers Recent facility acquisitions among solid-dose CDMOs/CMOs Other expansions Catalent Lonza Metrics...

In this podcast we feature a list of the Top 10 pharma CEOs to watch in 2020. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Pharma CEOs to watch in 2020 1. Three-way tie: Pfizer, J&J, and AstraZeneca. Pfizer Chairman and CEO Albert Bourla J&J Chairman and CEO Alex Gorsky AstraZeneca CEO Pascal Soriot 4. Moderna CEO Stéphane Bancel 5. Gilead Scie...

In this podcast we feature an article that looks at some key upcoming developments from the pipelines of the large pharmaceutical companies for new drugs or existing drugs with new indications with blockbuster potential. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Inside Big Pharma’s pipeline AbbVie Amgen/AstraZeneca AstraZeneca Bristol-Myers Squibb E...

In this podcast we feature a roundup of up expansions by CDMOs/CMOs and other suppliers in injectable drug development and manufacturing. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Injectable drugs and recent drug approvals Manufacturing expansions and technology advances A roundup of CDMO/CMO expansions thus far in 2020 Vetter Catalent Grand River A...

In this podcast we feature an article that looks at the small molecules approved as new molecular entities thus far in 2020 and which have blockbuster potential. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Small-molecule new drug approvals thus far in 2020 Small molecules and blockbuster potential Novo Nordisk’s Rybelsus Bristol-Myers Squibb’s Zeposia...

In this podcast we feature the top 10 deals thus far in 2020 and which pharma/biopharma companies are rising to the top. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) 1. Novartis’s $9.7-billion acquisition of The Medicines Company and Blackstone’s $2-billion investment in Alnylam  Pharmaceuticals. 2. Daiichi Sankyo’s  and AstraZeneca’s $6-billion ADC co...

In this podcast we feature an article that outlines the FDA’s proposed pilot program for the evaluation of novel excipients and summarizes industry feedback on the review program. For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Novel excipients and the FDA FDA’s view of a possible novel excipient review pilot program Industry feedback Links: Subscribe to ou...

In this podcast we feature an article that looks at the policy debate to repatriate and increase domestic drug manufacturing in the US in light of the COVID-19 pandemic and pharmaceutical supply-chain vulnerabilities. For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) A plan for addressing supply-chain vulnerabilities in the US Legislative proposals in the US...

In this podcast we feature an article that explores the future of digital medicines. For a text version of this article, visit dcatvci.org . Key topics: (see Chapter Markers) Digital medicines and digital health Digital health and digital medicines: a market view Pharma industry and digital health and digital medicines Links: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @D...

In this podcast we feature DCAT Value Chain Insights’ Top 10 Emerging Pharma Watch List based on recent high-value partnering deals. For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Emerging pharma strength 1.      Roivant Sciences 2.      Sangamo Therapeutics 3.      Silence Therapeutics 4.      Innovent Biologics 5.      Arcus Biosciences 6.      MorphoSys...

In this podcast we feature an article that looks at the near-term and long-term impact of the COVID-19 pandemic as biopharma companies re-access drug-development projects.  For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) The CDMO industry in the wake of COVID-19 Near-term outlook Medium-term could be challenging Longer-term implications Links: Subscribe to...

In this podcast, we round up key recent expansions in high-potency manufacturing by CDMOs and CMOs. For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Expansions in high-potency manufacturing Lonza WuXi AppTec Seqens Cambrex Piramal Pharma Solutions CordenPharma Flamma Cerbios-Pharma Evonik AGC Novasep Ajinomoto Bio-Pharma Services BSP Pharmaceuticals PCI Phar...

In this podcast, we feature an article about a recent DCAT Benchmarking study, conducted prior to COVID-19, that provides insights on whether biopharma companies and their suppliers believe the deteriorating trade environment is a major threat, and what they are doing to confront the real and potential risks to their supply chains. For a text version of this article visit dcatvci.org . Key topics:...

In this podcast, we feature an article that examines the new AbbVie, including the key products and expanded manufacturing networking, resulting from its recent acquisition of Allergan.  For a text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Inside the deal Inside the new AbbVie Links: Subscribe to our e-newsletter at www.dcatvci.org Follow us on Twitter @DCATvci...

In this podcast, we feature an article about the Association for Accessible Medicines’ blueprint to facilitate a repatriation of pharma manufacturing to the US. For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) A plan for re-inventing the US pharma supply chains A proposal for increasing US-based manufacturing for high-priority medicines List of essential m...

In this podcast, we outline the manufacturing strategies and alliances that are in play to develop and supply treatments and vaccines against COVID-19? For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Inside the numbers: tracking potential treatments and vaccines Supply lines for potential COVID-19 drugs and vaccines The supply lines: vaccines Ramping up p...

In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals.  For the text version of this article visit dcatvci.org . Key topics: (see Chapter Markers) Drug development and regulatory review FDA’s perspective New drug approvals thus far in 2020 Clinical trials and COVID-19: where the impact resides Com...